🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

great step forward in the management of locoregionally advanced melanoma!! congratulations to all the investigators

Just published in Annals of Oncology our study investigating intrapatient variation in PD-L1 & TMB and the impact on outcomes to #immunotherapy in patients with #NSCLC 🧵1/9 Dana-Farber News Dana-Farber's Lowe Center for Thoracic Oncology ESMO - Eur. Oncology IASLC OncoAlert OncLive.com #LCSM annalsofoncology.org/article/S0923-…

Just published in Journal of Clinical Oncology! First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data Professor Georgina Long AO (Bluesky @gvlongphdmd) Paolo A. Ascierto ascopubs.org/doi/full/10.12…

looking good Allison Betof Warner, MD, PhD !!

great poster from MSK on genetic drivers of non-acral melanoma in patients of different ancestries, races, and skin tones. #dermtwitter watch out for this superstar future dermatologist!! Vanessa Weir @alexshoushtari Columbia Vagelos College of Physicians & Surgeons Memorial Sloan Kettering Cancer Center Veronica Rotemberg, MD PhD

exciting opportunities ahead to improve on neoadjuvant checkpoint blockade in melanoma w intralesional therapies—congrats to Diwakar Davar, M.D. and colleagues on their trial of vidutolimod + aPD1 out this month in Cancer Cell  cell.com/cancer-cell/fu…

excited to hear Allison Betof Warner, MD, PhD ‘s take on what’s next in TIL therapy at melanoma bridge!

🎉Congrats to Yuan Chen Ronglai Shen Kathy Panageas for their Biometrics paper recently featured by MSK Library: Unlocking the power of multi-institutional data: Integrating and harmonizing genomic🧬 data across institutions🏥 dx.doi.org/10.1093/biomtc… #MSKBiostats

Want to get new cancer drugs in the next ten or twenty years? Impressed by the power of glp-1 obesity drugs? Fund the NIH.

"More than 99% of new drug approvals (2010-2019) were funded by NIH. Why dismantle the engine that made the U.S. a world leader in innovation and drug development ? #DoNotDefundScience jamanetwork.com/journals/jama-…

This Friday I'm riding with my colleagues in Cycle for Survival to raise money for rare melanoma research at Memorial Sloan Kettering Cancer Center, and your support would mean so much to me. Make a 100% tax-deductible donation using this link. Thank you! secure2.convio.net/mskcc/site/TR?…

Today, on #InternationalWomensDay, we celebrate and commit to fostering the career development of women in science every day, ensuring a robust and empowered cancer workforce dedicated to eradicating cancer. brnw.ch/21wRc3a

check out this month's special issue of transplantation and cellular therapy focused on TIL! enjoyed reviewing the clinical journey to date in melanoma with Allison Betof Warner, MD, PhD and Adam J. Schoenfeld sciencedirect.com/science/articl…

Looking forward to the exciting Oncology Learning Network live debates at Great Debates in Solid Tumors conference March 22nd in #NewYorkCity. Pleasure to join Jim Smithy & Dr Anna Pavlick. Agenda at the link👇 Moffitt Cancer Center Memorial Sloan Kettering Cancer Center Weill Cornell Medicine   hmpglobalevents.com/gdst/agenda

Super proud of Ali Toth on excellent presentation AANS NS Tumor Section & Master's eval'ing radiomic features vs multidisciplinary consensus in predicting #CNS #melanoma post-RT recurrence vs necrosis/heme. 🚨2026 nsgy applicant alert-she will match highly! Brain Metastasis Program @ MSK

Melanoma oncologist Jim Smithy speaks to attendees of ASCO about his research during poster sessions at #ASCO25.

fun morning at the melanoma poster session sharing our data on post-discharge toxicity for patients treated w lifileucel at MSK! many great abstracts across the spectrum of melanoma care #ASCO2025 Memorial Sloan Kettering Cancer Center

Congratulations to Kathryn Arbour Kathryn C. Arbour and colleagues showing activity of BMS-986504 in MTAP-deleted solid tumors, including lung and pancreas cancer. Memorial Sloan Kettering Cancer Center

Underway now in the #melanoma rapid oral abstract session at #ASCO25: Sarah E. Lochrin, MBBCh (Sarah E. Lochrin) from Memorial Sloan Kettering Cancer Center shares interim results from the C-IT Neo trial on single-dose neoadjuvant ipilimumab + nivolumab in resectable melanoma, with CD8+ PET imaging. ➡️